Ascorbic acid improves embryonic cardiomyoblast cell survival and promotes vascularization in potential myocardial grafts in vivo

Eliana Cecilia Martinez Valencia, Jing Wang, Shu Uin Gan, Rajeev Singh, Chuen Neng Lee, Theo Kofidis

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Organ restoration via cell therapy and tissue transplantation is limited by impaired graft survival. We tested the hypothesis that ascorbic acid (AA) reduces cell death in myocardial grafts both in vitro and in vivo and introduced a new model of autologous graft vascularization for later transplantation. Luciferase (Fluc)- and green fluorescent protein (GFP)-expressing H9C2 cardiomyoblasts were seeded in gelatin scaffolds to form myocardial artificial grafts (MAGs). MAGs were supplemented with AA (5 or 50μmol/L) or plain growth medium. Bioluminescence imaging showed increased cell photon emission from day 1 to 5 in grafts supplemented with 5μmol/L (p<0.001) and 50μmol/L (p<0.01) AA. The amount of apoptotic cells in plain MAGs was significantly higher than in AA-enriched grafts. In our in vitro model, AA also enhanced H9C2 cell myogenic differentiation. For in vivo studies, MAGs containing H9C2-GFP-Fluc cells and enriched with AA (n=10) or phosphate-buffered saline (n=10) were implanted in the renal pouch of Wistar rats. At day 6, postimplantation bioluminescence signals decreased by 74% of baseline in plain MAGs versus 36% in AA-enriched MAGs (p<0.0001). AA grafts contained significantly higher amounts of blood vessels, GFP+ donor cells, and endothelial cells. In this study, we identified AA as a potent supplement that improves cardiomyoblast survival and promotes neovascularization in bioartificial grafts.

Original languageEnglish (US)
Pages (from-to)1349-1361
Number of pages13
JournalTissue Engineering - Part A
Volume16
Issue number4
DOIs
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

Ascorbic acid
Grafts
Ascorbic Acid
Cell Survival
Cells
Transplants
Green Fluorescent Proteins
Transplantation (surgical)
Bioluminescence
Proteins
Tissue Transplantation
Forms (concrete)
Cell Transplantation
Graft Survival
Gelatin
Cell- and Tissue-Based Therapy
Endothelial cells
Blood vessels
Luciferases
Photons

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomedical Engineering
  • Biomaterials
  • Medicine(all)

Cite this

Ascorbic acid improves embryonic cardiomyoblast cell survival and promotes vascularization in potential myocardial grafts in vivo. / Martinez Valencia, Eliana Cecilia; Wang, Jing; Gan, Shu Uin; Singh, Rajeev; Lee, Chuen Neng; Kofidis, Theo.

In: Tissue Engineering - Part A, Vol. 16, No. 4, 01.04.2010, p. 1349-1361.

Research output: Contribution to journalArticle

Martinez Valencia, Eliana Cecilia ; Wang, Jing ; Gan, Shu Uin ; Singh, Rajeev ; Lee, Chuen Neng ; Kofidis, Theo. / Ascorbic acid improves embryonic cardiomyoblast cell survival and promotes vascularization in potential myocardial grafts in vivo. In: Tissue Engineering - Part A. 2010 ; Vol. 16, No. 4. pp. 1349-1361.
@article{1f0aea07ce994d6ead4a596de67b1bdf,
title = "Ascorbic acid improves embryonic cardiomyoblast cell survival and promotes vascularization in potential myocardial grafts in vivo",
abstract = "Organ restoration via cell therapy and tissue transplantation is limited by impaired graft survival. We tested the hypothesis that ascorbic acid (AA) reduces cell death in myocardial grafts both in vitro and in vivo and introduced a new model of autologous graft vascularization for later transplantation. Luciferase (Fluc)- and green fluorescent protein (GFP)-expressing H9C2 cardiomyoblasts were seeded in gelatin scaffolds to form myocardial artificial grafts (MAGs). MAGs were supplemented with AA (5 or 50μmol/L) or plain growth medium. Bioluminescence imaging showed increased cell photon emission from day 1 to 5 in grafts supplemented with 5μmol/L (p<0.001) and 50μmol/L (p<0.01) AA. The amount of apoptotic cells in plain MAGs was significantly higher than in AA-enriched grafts. In our in vitro model, AA also enhanced H9C2 cell myogenic differentiation. For in vivo studies, MAGs containing H9C2-GFP-Fluc cells and enriched with AA (n=10) or phosphate-buffered saline (n=10) were implanted in the renal pouch of Wistar rats. At day 6, postimplantation bioluminescence signals decreased by 74{\%} of baseline in plain MAGs versus 36{\%} in AA-enriched MAGs (p<0.0001). AA grafts contained significantly higher amounts of blood vessels, GFP+ donor cells, and endothelial cells. In this study, we identified AA as a potent supplement that improves cardiomyoblast survival and promotes neovascularization in bioartificial grafts.",
author = "{Martinez Valencia}, {Eliana Cecilia} and Jing Wang and Gan, {Shu Uin} and Rajeev Singh and Lee, {Chuen Neng} and Theo Kofidis",
year = "2010",
month = "4",
day = "1",
doi = "10.1089/ten.tea.2009.0399",
language = "English (US)",
volume = "16",
pages = "1349--1361",
journal = "Tissue Engineering - Part A",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Ascorbic acid improves embryonic cardiomyoblast cell survival and promotes vascularization in potential myocardial grafts in vivo

AU - Martinez Valencia, Eliana Cecilia

AU - Wang, Jing

AU - Gan, Shu Uin

AU - Singh, Rajeev

AU - Lee, Chuen Neng

AU - Kofidis, Theo

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Organ restoration via cell therapy and tissue transplantation is limited by impaired graft survival. We tested the hypothesis that ascorbic acid (AA) reduces cell death in myocardial grafts both in vitro and in vivo and introduced a new model of autologous graft vascularization for later transplantation. Luciferase (Fluc)- and green fluorescent protein (GFP)-expressing H9C2 cardiomyoblasts were seeded in gelatin scaffolds to form myocardial artificial grafts (MAGs). MAGs were supplemented with AA (5 or 50μmol/L) or plain growth medium. Bioluminescence imaging showed increased cell photon emission from day 1 to 5 in grafts supplemented with 5μmol/L (p<0.001) and 50μmol/L (p<0.01) AA. The amount of apoptotic cells in plain MAGs was significantly higher than in AA-enriched grafts. In our in vitro model, AA also enhanced H9C2 cell myogenic differentiation. For in vivo studies, MAGs containing H9C2-GFP-Fluc cells and enriched with AA (n=10) or phosphate-buffered saline (n=10) were implanted in the renal pouch of Wistar rats. At day 6, postimplantation bioluminescence signals decreased by 74% of baseline in plain MAGs versus 36% in AA-enriched MAGs (p<0.0001). AA grafts contained significantly higher amounts of blood vessels, GFP+ donor cells, and endothelial cells. In this study, we identified AA as a potent supplement that improves cardiomyoblast survival and promotes neovascularization in bioartificial grafts.

AB - Organ restoration via cell therapy and tissue transplantation is limited by impaired graft survival. We tested the hypothesis that ascorbic acid (AA) reduces cell death in myocardial grafts both in vitro and in vivo and introduced a new model of autologous graft vascularization for later transplantation. Luciferase (Fluc)- and green fluorescent protein (GFP)-expressing H9C2 cardiomyoblasts were seeded in gelatin scaffolds to form myocardial artificial grafts (MAGs). MAGs were supplemented with AA (5 or 50μmol/L) or plain growth medium. Bioluminescence imaging showed increased cell photon emission from day 1 to 5 in grafts supplemented with 5μmol/L (p<0.001) and 50μmol/L (p<0.01) AA. The amount of apoptotic cells in plain MAGs was significantly higher than in AA-enriched grafts. In our in vitro model, AA also enhanced H9C2 cell myogenic differentiation. For in vivo studies, MAGs containing H9C2-GFP-Fluc cells and enriched with AA (n=10) or phosphate-buffered saline (n=10) were implanted in the renal pouch of Wistar rats. At day 6, postimplantation bioluminescence signals decreased by 74% of baseline in plain MAGs versus 36% in AA-enriched MAGs (p<0.0001). AA grafts contained significantly higher amounts of blood vessels, GFP+ donor cells, and endothelial cells. In this study, we identified AA as a potent supplement that improves cardiomyoblast survival and promotes neovascularization in bioartificial grafts.

UR - http://www.scopus.com/inward/record.url?scp=77950836038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950836038&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2009.0399

DO - 10.1089/ten.tea.2009.0399

M3 - Article

C2 - 19908964

AN - SCOPUS:77950836038

VL - 16

SP - 1349

EP - 1361

JO - Tissue Engineering - Part A

JF - Tissue Engineering - Part A

SN - 1937-3341

IS - 4

ER -